India is the third-largest drug producer by volume and roughly eleventh to fourteenth by value — a gap that describes the whole industry. It supplies about 20% of the world's generic medicines and 60% of its vaccine doses, yet imports around 70% of its own APIs and key starting materials from China. Read the chain top to bottom: value accumulates at stages 3 and 8, the structural weakness sits at stage 2, and stage 5 is a gate rather than a market. Tap any stage to open it, then any company for detail.
At the head of this chain
Highest return on capital and fastest sustained sales growth among the 89 listed companies in this chain above ₹1,000 Cr market cap and ₹500 Cr revenue. Sustained growth is the lower of the 3-year and 5-year sales CAGR, so a single strong year cannot win it — Manipal Health Enterprises compounded 29.1% over three years and 41.6% over five. Same rule on every map. Snapshot 8 Sep 2026.
How Indian pharmaceuticals works
Nine stages, from discovery to the patient. Where the money actually collects.
- Margin pool
- Highest at branded formulations — Abbott India earns 44.8% and GSK Pharma 61.4% on capital, selling brands through a field force with almost no plant. Lowest at APIs and intermediates, where Chinese oversupply sets the price, and in distribution, where stockists work on low single-digit margins.
- Bargaining power
- Brand owners hold power over API suppliers and over the trade. Regulators hold power over everyone — a USFDA import alert removes a plant's revenue overnight. In US generics the buyer holds it: three purchasing consortia set the price for the entire market.
- Demand or supply led
- Supply-led in exports, where price is set by whoever adds capacity, and demand-led at home, where the prescription creates the sale. Chronic therapies are the growth engine because they repeat.
- Who owns the customer
- Nobody in this chain owns the patient. The doctor prescribes, the chemist bills, and the patient pays — out of pocket for roughly 43% of Indian health spending. The brand owner never meets the person taking the medicine, which is why field-force reach matters more than marketing.
- Barriers to entry
- Lowest in trade generics and distribution: capital-light and crowded. Highest in regulated-market manufacturing — a USFDA-compliant plant, complex injectables and biosimilars take years and hundreds of crores to qualify.
- Threat of substitutes
- Generic substitution is the substitute, and it is the whole industry. Biosimilars now do to biologics what generics did to small molecules. Domestically, Jan Aushadhi unbranded generics are the structural threat to branded-generic pricing.
This is a generalist read of how the industry typically works, not a rule. Anomalies exist at every stage — a well-run company in a poor part of the chain routinely beats a badly-run one in a good part, and structure changes with the cycle. Use it as a starting frame, not a conclusion.
No company matches that search.